1. It has been ~5 years now that they have been marketing and selling the Axiron product. I thought by now they would be much closer to commercialisation and distribution of another (meaningful) product line.
2. Overpaid staff
3. Lack of compliance and shareholder communication. A trading halt should have been requested during pre open following the FDA announcement night before
The FDA announcement in Sep I personally did not thinking it was a big deal. A more detailed warning label is required.....but investors read it as extremely negative - please correct me if my understanding of this is wrong?
Cheers
38 vs. 89, page-6
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
-0.002(4.08%) |
Mkt cap ! $14.24M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.6¢ | $15.47K | 324.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 154451 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 120000 | 1 |
View Market Depth
| Last trade - 15.17pm 11/11/2024 (20 minute delay) ? |
| ACR (ASX) Chart |